Abstract
Liver X Receptor-α (LXRα, also known as NR1H3) and LXRβ (NR1H2) are members of the nuclear receptor superfamily of ligand-activated transcription factors, a superfamily which includes the more widely known glucocorticoid receptor, estrogen receptor, thyroid receptor, and peroxisome proliferator-activated receptors. The LXRs are activated by physiologic sterol ligands (e.g., oxysterols) and by synthetic agonists. In recent years, our understanding of the importance of LXRs has expanded across several fields of (patho-) physiology. Perhaps best known from a sizeable literature as homeostatic ‘cholesterol sensors’ that drive transcriptional programs promoting cellular cholesterol efflux, ‘reverse cholesterol transport,’ and bile acid synthesis, more recent roles for LXRs in glucose homeostasis, atherosclerosis, and innate immunity have also been identified. These discoveries complement an emerging literature that continues to draw surprisingly intimate connections between host metabolism and host defense. The present review will discuss the roles of LXR in the signaling of metabolism and innate immunity, and the potential for synthetic LXR agonists as novel therapeutics in dyslipidemia, atherosclerosis, disordered glucose metabolism, and inflammation.
Keywords: Liver X receptor, innate immunity, cholesterol, inflammation
Current Signal Transduction Therapy
Title: Liver X Receptor: Crosstalk Node for the Signaling of Lipid Metabolism,Carbohydrate Metabolism, and Innate Immunity
Volume: 3 Issue: 2
Author(s): Michael B. Fessler
Affiliation:
Keywords: Liver X receptor, innate immunity, cholesterol, inflammation
Abstract: Liver X Receptor-α (LXRα, also known as NR1H3) and LXRβ (NR1H2) are members of the nuclear receptor superfamily of ligand-activated transcription factors, a superfamily which includes the more widely known glucocorticoid receptor, estrogen receptor, thyroid receptor, and peroxisome proliferator-activated receptors. The LXRs are activated by physiologic sterol ligands (e.g., oxysterols) and by synthetic agonists. In recent years, our understanding of the importance of LXRs has expanded across several fields of (patho-) physiology. Perhaps best known from a sizeable literature as homeostatic ‘cholesterol sensors’ that drive transcriptional programs promoting cellular cholesterol efflux, ‘reverse cholesterol transport,’ and bile acid synthesis, more recent roles for LXRs in glucose homeostasis, atherosclerosis, and innate immunity have also been identified. These discoveries complement an emerging literature that continues to draw surprisingly intimate connections between host metabolism and host defense. The present review will discuss the roles of LXR in the signaling of metabolism and innate immunity, and the potential for synthetic LXR agonists as novel therapeutics in dyslipidemia, atherosclerosis, disordered glucose metabolism, and inflammation.
Export Options
About this article
Cite this article as:
Fessler B. Michael, Liver X Receptor: Crosstalk Node for the Signaling of Lipid Metabolism,Carbohydrate Metabolism, and Innate Immunity, Current Signal Transduction Therapy 2008; 3 (2) . https://dx.doi.org/10.2174/157436208784223170
DOI https://dx.doi.org/10.2174/157436208784223170 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
NS3 Helicases as Drug Targets
Current Chemical Biology Humanized Mouse Models of HIV-1 Latency
Current HIV Research Small Molecule Antagonists of the Chemokine Receptor CCR5
Current Topics in Medicinal Chemistry Could Hippocampal Neurogenesis be a Future Drug Target for Treating Temporal Lobe Epilepsy?
CNS & Neurological Disorders - Drug Targets AD Vaccines: Conclusions and Future Directions
CNS & Neurological Disorders - Drug Targets Mouse Models of Autoimmune Uveitis
Current Pharmaceutical Design Therapeutic Targeting of Chemokines and Chemokine Receptors in Multiple Sclerosis: Opportunities and Challenges
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic:Advances in Alzheimer Therapy: Understanding Pharmacological Approaches to the Disease (Guest Editors: Ana Martinez, Debomoy K. Lahiri, Ezio Giacobini and Nigel H. Greig)]
Current Alzheimer Research Recent Advances in the Imaging of Programmed Cell Death
Current Pharmaceutical Design Inhibition of Viral-Induced Membrane Fusion by Peptides
Protein & Peptide Letters Astrocytes and Inflammasome: A Possible Crosstalk in Neurological Diseases
Current Medicinal Chemistry Current Status Of Short Synthetic Peptides As Vaccines
Medicinal Chemistry Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Beyond Cholinesterase Inhibition: Anti-Inflammatory Role and Pharmacological Profile of Current Drug Therapy for Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Overview on the Tricks of HIV Tat to Hit the Blood Brain Barrier
Current HIV Research Inflammatory Risk Factors and Pathologies Associated with Alzheimers Disease
Current Alzheimer Research Current Experimental Therapy for Alzheimers Disease
Current Neuropharmacology Porphyrin Photosensitised Processes in the Prevention and Treatment of Water- and Vector-Borne Diseases
Current Medicinal Chemistry A Critical Analysis of New Molecular Targets and Strategies for Drug Developments in Alzheimers Disease
Current Drug Targets Multiple Roles for Chemokines in the Pathogenesis of SIV Infection
Current HIV Research